Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Dec;102(3):575–581. doi: 10.1111/j.1365-2249.1995.tb03855.x

Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

H V Marquart 1, K Grønbaek 1, B E Christensen 1, S E Svehag 1, R G Leslie 1
PMCID: PMC1553367  PMID: 8536375

Abstract

It has previously been reported that the expression of the complement receptors CR1 (CD35) and CR2 (CD21) on malignant B cells in CLL is reduced compared with the expression on normal B cells, while deposition of complement C3 fragments, as a consequence of alternative pathway (AP) activation of complement, is observed on mononuclear cells from patients with B CLL. Following our demonstration that normal B cells are capable of activating the AP of complement in a CR2-dependent fashion, we have chosen to re-examine the complement-activating ability of B CLL cells in relation to their altered phenotype with respect to CR2 and the complement regulatory membrane proteins, CR1, decay accelerating factor (DAF) (CD55) and membrane cofactor protein (MCP) (CD46). Flow cytometry was used to measure expression of complement receptors and regulatory proteins on CD5+ B cells from CLL patients, as well as the deposition of C3 fragments occurring both in vivo and after in vitro AP activation. We have confirmed the reduced expression of CR1 and CR2 on CLL cells and have shown that AP activation in the presence of homologous, normal serum was reduced on B CLL cells compared with normal B cells. The degree of AP activation correlated directly with CR2 expression. In addition, we observed that CLL cells bear in vivo-deposited C3d,g, although at a significantly lower level than normal B cells.

Full text

PDF
575

Images in this article

579Fig. 5
on p.579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198–206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  2. Boumsell L., Bernard A., Lepage V., Degos L., Lemerle J., Dausset J. Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol. 1978 Dec;8(12):900–904. doi: 10.1002/eji.1830081214. [DOI] [PubMed] [Google Scholar]
  3. Budzko D. B., Lachmann P. J., McConnell I. Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol. 1976 Mar 1;22(1):98–109. doi: 10.1016/0008-8749(76)90011-3. [DOI] [PubMed] [Google Scholar]
  4. Casali P., Burastero S. E., Nakamura M., Inghirami G., Notkins A. L. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science. 1987 Apr 3;236(4797):77–81. doi: 10.1126/science.3105056. [DOI] [PubMed] [Google Scholar]
  5. Cheung N. K., Walter E. I., Smith-Mensah W. H., Ratnoff W. D., Tykocinski M. L., Medof M. E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988 Apr;81(4):1122–1128. doi: 10.1172/JCI113426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Christensen J., Leslie R. G. Quantitative measurement of Fc receptor activity on human peripheral blood monocytes and the monocyte-like cell line, U937, by laser flow cytometry. J Immunol Methods. 1990 Sep 14;132(2):211–219. doi: 10.1016/0022-1759(90)90032-q. [DOI] [PubMed] [Google Scholar]
  7. Cooper N. R., Moore M. D., Nemerow G. R. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Annu Rev Immunol. 1988;6:85–113. doi: 10.1146/annurev.iy.06.040188.000505. [DOI] [PubMed] [Google Scholar]
  8. Deegan M. J., Maeda K. Differentiation of chronic lymphocytic leukemia cells after in vitro treatment with Epstein-Barr virus or phorbol ester. I. Immunologic and morphologic studies. Am J Hematol. 1984;17(4):335–347. doi: 10.1002/ajh.2830170403. [DOI] [PubMed] [Google Scholar]
  9. Erdei A., Füst G., Gergely J. The role of C3 in the immune response. Immunol Today. 1991 Sep;12(9):332–337. doi: 10.1016/0167-5699(91)90011-H. [DOI] [PubMed] [Google Scholar]
  10. Freedman A. S., Boyd A. W., Berrebi A., Horowitz J. C., Levy D. N., Rosen K. J., Daley J., Slaughenhoupt B., Levine H., Nadler L. M. Expression of B cell activation antigens on normal and malignant B cells. Leukemia. 1987 Jan;1(1):9–15. [PubMed] [Google Scholar]
  11. Fu S. M., Chiorazzi N., Kunkel H. G. Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol Rev. 1979;48:23–44. doi: 10.1111/j.1600-065x.1979.tb00297.x. [DOI] [PubMed] [Google Scholar]
  12. Fu S. M., Winchester R. J., Rai K. R., Kunkel H. G. Hairy cell leukemia: proliferation of a cell with phagocytic and B-lymphocyte properties. Scand J Immunol. 1974;3(6):847–851. doi: 10.1111/j.1365-3083.1974.tb01322.x. [DOI] [PubMed] [Google Scholar]
  13. Gordon J., Walker L., Guy G., Brown G., Rowe M., Rickinson A. Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology. 1986 Aug;58(4):591–595. [PMC free article] [PubMed] [Google Scholar]
  14. Grey H. M., Rabellino E., Pirofsky B. Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest. 1971 Nov;50(11):2368–2375. doi: 10.1172/JCI106735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hamblin T. J., Jones J. V., Peacock D. B. The immune response to phichi174 in man. IV. Primary and secondary antibody production in patients with chronic lymphatic leukaemia. Clin Exp Immunol. 1975 Jul;21(1):101–108. [PMC free article] [PubMed] [Google Scholar]
  16. Hara T., Kojima A., Fukuda H., Masaoka T., Fukumori Y., Matsumoto M., Seya T. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol. 1992 Oct;82(2):368–373. doi: 10.1111/j.1365-2141.1992.tb06431.x. [DOI] [PubMed] [Google Scholar]
  17. Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381–416. doi: 10.1016/s0065-2776(08)60697-5. [DOI] [PubMed] [Google Scholar]
  18. Lindahl T., Klein G., Reedman B. M., Johansson B., Singh S. Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer. 1974 Jun 15;13(6):764–772. doi: 10.1002/ijc.2910130605. [DOI] [PubMed] [Google Scholar]
  19. McConnell I., Klein G., Lint T. F., Lachmann P. J. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol. 1978 Jul;8(7):453–458. doi: 10.1002/eji.1830080702. [DOI] [PubMed] [Google Scholar]
  20. Mole L. E., Geier M. D., Koshland M. E. The isolation and characterization of the V-H domain from rabbit heavy chains of different a locus allotype. J Immunol. 1975 May;114(5):1442–1448. [PubMed] [Google Scholar]
  21. Nemerow G. R., Wolfert R., McNaughton M. E., Cooper N. R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol. 1985 Aug;55(2):347–351. doi: 10.1128/jvi.55.2.347-351.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Praz F., Karsenty G., Binet J. L., Lesavre P. Complement alternative pathway activation by chronic lymphocytic leukemia cells: its role in their hepatosplenic localization. Blood. 1984 Feb;63(2):463–467. [PubMed] [Google Scholar]
  23. Ramos O. F., Sármay G., Klein E., Yefenof E., Gergely J. Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci U S A. 1985 Aug;82(16):5470–5474. doi: 10.1073/pnas.82.16.5470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Royston I., Majda J. A., Baird S. M., Meserve B. L., Griffiths J. C. Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol. 1980 Aug;125(2):725–731. [PubMed] [Google Scholar]
  25. Schulz T., Dierich M. P., Yefenof E., Klein G. C3-activating proteases on human lymphoblastoid cells superinfected with Epstein-Barr Virus. Cell Immunol. 1980 Apr;51(1):168–172. doi: 10.1016/0008-8749(80)90246-4. [DOI] [PubMed] [Google Scholar]
  26. Seya T., Hara T., Matsumoto M., Akedo H. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol. 1990 Jul 1;145(1):238–245. [PubMed] [Google Scholar]
  27. Stashenko P., Nadler L. M., Hardy R., Schlossman S. F. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3848–3852. doi: 10.1073/pnas.78.6.3848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sthoeger Z. M., Wakai M., Tse D. B., Vinciguerra V. P., Allen S. L., Budman D. R., Lichtman S. M., Schulman P., Weiselberg L. R., Chiorazzi N. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989 Jan 1;169(1):255–268. doi: 10.1084/jem.169.1.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tedder T. F., Clement L. T., Cooper M. D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol. 1984 Aug;133(2):678–683. [PubMed] [Google Scholar]
  30. Teisner B., Brandslund I., Folkersen J., Rasmussen J. M., Poulsen L. O., Svehag S. E. Factor I deficiency and C3 nephritic factor: immunochemical findings and association with Neisseria meningitidis infection in two patients. Scand J Immunol. 1984 Oct;20(4):291–297. doi: 10.1111/j.1365-3083.1984.tb01005.x. [DOI] [PubMed] [Google Scholar]
  31. Tooze J. A., Bevan D. H. Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia. Clin Exp Immunol. 1991 Mar;83(3):423–429. doi: 10.1111/j.1365-2249.1991.tb05655.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Werner-Favre C., Vischer T. L., Wohlwend D., Zubler R. H. Cell surface antigen CD5 is a marker for activated human B cells. Eur J Immunol. 1989 Jul;19(7):1209–1213. doi: 10.1002/eji.1830190709. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES